| | |
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| Chemical and physical data | |
| Formula | C23H30N2OS |
| Molar mass | 382.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
A-PBITMO is a synthetic cannabinoid receptor agonist that has been sold as a designer drug, first reported in Germany in July 2023, [1] and also subsequently identified in Russia. [2] It has an unusual 1,3-dihydrobenzimidazole-2-thione core structure which has not previously been seen in cannabinoid designer drugs.
| Receptor (ligands) |
| ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||||||||||||||||||||
| Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |